CytoSorbents Corp (CTSO): Kapitalisasi marang pendapatan

Cytosorbents is successfully implementing unique sorption filters, avoiding dumping through technological superiority. The company's P/S ratio confirms this trend, with the value holding at 0.50. Growth is based on the expansion of B2B sales of CytoSorb systems in clinics. High authority among surgeons and a track record of saving patients with sepsis solidify its status as a global leader in blood purification.

Assessing the investment potential of Cytosorbents (CTSO) requires an analysis of the ratio between market value and actual cash flows. This price-to-sales ratio measures capitalization per unit of sales, allowing for the identification of asset overheating. In the context of CytoSorb technology maturity, this metric reflects the monetization efficiency of blood purification systems. The indicator's dynamics help investors compare the pace of expansion into new niches with current market expectations.